RIVASTIGMINE GenPar PATCH 15 rivastigmine 13.3 mg/24 hours transdermal drug delivery system sachet

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

rivastigmine, Quantity: 27 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

Rivastigmine

formulario farmacéutico:

Drug delivery system, transdermal

Composición:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Vía de administración:

Transdermal

Unidades en paquete:

7 sachets, 30 sachets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

RIVASTIGMINE GENPAR PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.

Resumen del producto:

Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2017-01-25